跳到正文
原文
Nature 健康护理主题·· 25 天前AI 评分35

初次选择质子泵抑制剂对急性胃食管反流加重6小时烧心严重程度的影响:一项前瞻性双中心队列研究

Initial proton pump inhibitor choice and 6-hour heartburn severity in acute reflux exacerbation: a prospective two-centre cohort study

AI 导读

一项前瞻性双中心队列研究显示,189名急性胃食管反流加重患者中,初次选择的质子泵抑制剂(dexrabeprazole、esomeprazole、pantoprazole)在首次给药后6小时的烧心视觉模拟评分(VAS)中,dexrabeprazole和esomeprazole均显著低于pantoprazole(p<0.007)。

正文

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Acute exacerbations of gastro-oesophageal reflux disease commonly bring patients to emergency departments, where rapid symptom control matters more than mucosal healing, yet head-to-head data on symptom severity in the first hours after an oral dose are scarce. In this prospective two-centre cohort study, 189 adults with an acute reflux exacerbation and a Gastroesophageal Reflux Disease Questionnaire score of 8 or more received dexrabeprazole 10 mg, esomeprazole 20 mg or pantoprazole 40 mg, chosen by the treating physician before enrolment. The primary outcome was heartburn visual analogue scale (VAS) score six hours after the first dose, analysed by analysis of covariance adjusted for baseline VAS and nine covariates. The overall adjusted group effect was significant (F(2,171) = 6.32; p = 0.002). Adjusted six-hour VAS was lower with dexrabeprazole than pantoprazole (− 0.83 points, 95% confidence interval − 1.36 to − 0.30) and than esomeprazole (− 0.77, − 1.27 to − 0.27; both Holm-adjusted p = 0.007); comparators showed no detectable difference. In a post hoc exploratory analysis, adjusted probabilities of ≥ 50% heartburn reduction were 68.3%, 31.5% and 33.7%. Treatment was not randomly allocated and the analysis plan followed data collection, so these findings concern prescribing regimens rather than equipotent doses, are hypothesis-generating and require randomised confirmation.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. No pharmaceutical company had any role in the design of the study, the collection, analysis or interpretation of the data, or the preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Emergency Medicine, Ankara Etlik City Hospital, VarlıkMahallesi, Halil Sezai Erkut Caddesi No: 5, 06170, Yenimahalle, Ankara, Turkey

    İsmail Borazan, Hamdi Haluk Çalı, Bahadır Karaca & İlker Şirin

  2. Department of Emergency Medicine, Faculty of Medicine, Kırşehir Ahi Evran University, Kırşehir, Turkey

    Hacı Mehmet Çalışkan

Authors

  1. İsmail Borazan
  2. Hacı Mehmet Çalışkan
  3. Hamdi Haluk Çalı
  4. Bahadır Karaca
  5. İlker Şirin

Corresponding author

Correspondence to İsmail Borazan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

The study was approved by the Scientific Research Evaluation and Ethics Committee No. 1 of Ankara Etlik City Hospital (approval number AEŞH-EK-2026-101, dated 13 May 2026) and was conducted in accordance with the Declaration of Helsinki and its later amendments.

Consent to participate

Written informed consent to participate was obtained from all participants.

Consent to publish

Not applicable; the manuscript contains no individually identifiable data.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Borazan, İ., Çalışkan, H.M., Çalı, H.H. et al. Initial proton pump inhibitor choice and 6-hour heartburn severity in acute reflux exacerbation: a prospective two-centre cohort study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-75924-z

Download citation

  • Received: 04 September 2026

  • Accepted: 09 October 2026

  • Published: 26 October 2026

  • DOI: https://doi.org/10.1038/s41598-026-75924-z

Keywords

来源:Nature 健康护理主题 · nature.com